Novartis puts contract manufacturing ambitions on display with deal to produce Carisma's cell therapy

It turns out Novartis has a taste for the contract manufacturing business. After inking a slate of pandemic production pacts last year, the Swiss pharma is back for another—and this time, it’s looking beyond COVID-19.

Novartis has penned an initial deal to manufacture Carisma Therapeutics’ HER2-targeted CAR-M cell therapy, which is currently in initial studies to treat solid tumors.